Bliss GVS Pharma Limited — Important, 08-07-2025: General Updates

Bliss GVS Pharma has announced a board meeting to consider the financial results for the quarter and half-year. The company’s Board has approved a final dividend of Re. 0.50 per equity share for FY 2024-25, subject to shareholder approval. Dividend income will be taxable in shareholders' hands with tax deducted at source as applicable. Shareholders must ensure their PAN, KYC, and bank details are updated to avoid higher TDS rates and ensure smooth dividend credit. Non-resident shareholders can avail of DTAA benefits by submitting required documentation. The company will issue TDS certificates post dividend payment.